Floatz logo

Inno-206

Mixed Oligoastrocytoma

Washington University School of MedicinePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Mixed Oligoastrocytoma cohort.

Asset / SponsorPhaseRating
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 1/2BB
CHLOROTOXIN
TransMolecular
Phase 2CCC
ETOPOSIDE
Washington University School of Medicine
Phase 2CCC
GBM6-AD
Jennie Taylor
Phase 1CC
Interferon Beta
Biogen
Phase 1CC

View all 12 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →